Full-Time

Supervisor

Manufacturing, Clinical Drug Product

Posted on 9/10/2024

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines for health

Biotechnology
Healthcare

Mid, Senior

Norwood, MA, USA

This position is site-based, requiring full-time presence at Moderna’s site.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • STEM degree with 3-5 years’ industry experience or an Associates’ degree with 5-8 years’ industry experience or HS Diploma with 8 years’ industry experience
  • Position requires working/standing in Grade C room for a minimum of 5 hours per day.
  • Thorough knowledge and understanding of cGMPs and FDA guidelines is required.
Responsibilities
  • Safely and compliantly fill and label mRNA medicines
  • Ensure plans and resources (people, facilities, supplies etc.) are efficiently utilized to manufacture mRNA medicines and deliver on time to the clinic. This requires clear communication to cross functional peers on a daily basis.
  • Oversee the hiring, training, development, retention, and performance of staff for the execution of clinical manufacturing operations.
  • Develop batch records, SOPs, and training materials as needed for various phases of clinical programs at the Norwood Facility
  • Closely partner with QA peers for closure of documentation required for timely disposition of clinical batches.
  • Develop comprehensive operating plans to ensure success of direct team and communication to other clinical platform teams. These plans will align with corporate goals and clinical trial demand.
  • Effectively escalate information to Clinical Manufacturing management as required.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for various biological functions. Their approach involves using mRNA to instruct cells to create specific proteins that can help treat diseases. This method differs from traditional drug development by potentially allowing for faster and more efficient creation of vaccines and therapies. Unlike many pharmaceutical companies that rely on established methods, Moderna is at the forefront of mRNA technology, aiming to transform how medicines are discovered and manufactured. The company's goal is to improve patient outcomes by harnessing the power of mRNA to create new treatments.

Company Stage

IPO

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

2010

Growth & Insights
Headcount

6 month growth

4%

1 year growth

16%

2 year growth

55%
Simplify Jobs

Simplify's Take

What believers are saying

  • Opening a new vaccine facility in Victoria enhances Moderna's manufacturing capabilities.
  • Strategic investment in China boosts Moderna's presence in the Asian market.
  • Collaboration with Carisma Therapeutics expands mRNA applications to autoimmune diseases.

What critics are saying

  • Potential removal from Nasdaq 100 could impact investor perception and stock liquidity.
  • Reticence in Hong Kong for COVID-19 jab indicates market acceptance challenges.
  • Expansion into China may expose Moderna to geopolitical risks and regulatory challenges.

What makes Moderna unique

  • Moderna is pioneering mRNA technology for a new class of medicines.
  • The company has developed one of the earliest and most effective COVID-19 vaccines.
  • Moderna's mRNA platform targets infectious diseases, immuno-oncology, and autoimmune diseases.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE